Fig. 4.

Epigenetic repression of CDK4 and CDK6 expression induced by nafamostat mesylate in endocrine-resistant estrogen receptor-positive breast cancer cells. (A) Levels of CDK families in MCF7-TamR (upper) and -FulR (lower) cells treated with a serial dose of NM, assessed using western blot analysis with specific antibodies. (B) mRNA levels of CDK4 and CDK6 in MCF7-TamR (upper) and -FulR (lower) cells treated with serial doses of NM, assessed using quantitative PCR assay. (C) Acetylation levels of histone 3 in MCF7-TamR (upper) and -FulR (lower) cells treated with serial doses of NM, assessed using western blot analysis with specific antibodies. (D) A simple diagram for the P1, P2, P3, and P4 regions of CDK4 (left) and CDK6 (right). (E) Binding levels of Histone 3 Lysine 27 at the promoter region of CDK4 n MCF7-TamR (left) and -FulR (right) cells treated with serial doses of NM, assessed using qChIP-PCR assays. (F) Binding levels of Histone 3 Lysine 27 at the promoter region of CDK6 in MCF-TamR (left) and -FulR (right) cells treated with serial doses of NM, assessed using qChIP-PCR assay. Data are represented as the mean ± SEM for biological triplicate experiments. ^⁎#P < 0.01, compared with the results for untreated MCF7-FulR and MCF7-TamR cells.